Consultant in General Paediatrics and Vaccinology, Honorary Senior Clinical Lecturer, Group Head / PI, Consultant Physician and Member of congregation
Dr Matthew Snape, MBBS FRCPCH MD, is a Consultant in General Paediatrics and Vaccinology at the NIHR Oxford Biomedical Research Council and the Children’s Hospital Oxford, Oxford University Hospitals NHS Trust. He is also an Honorary Senior Clinical Lecturer at the Department of Paediatrics, University of Oxford, a Jenner Investigator and a fellow of St Cross College, Oxford.
Dr Snape's principal areas of research relate to vaccines against meningococcal, pneumococcal, and influenza, and prevention of disease through maternal immunisation. In 2014/2015 he was the lead investigator on a 'first in human' phase 1 study of a candidate ebola vaccine, providing data crucial to the planning of subsequent studies in West Africa.
Dr Snape graduated from the University of Melbourne in 1993 and completed his basic paediatric training at the Royal Children’s Hospital, Melbourne before continuing his training at St Mary’s Hospital, London. While working in the Paediatric Intensive Care Unit at St Mary’s hospital he became interested in the prevention of invasive meningococcal disease by immunisation, and on completion of his clinical training took up a post as a research fellow (later Clinical Lecturer) at the Oxford Vaccine Group, University of Oxford. While here he completed his post- graduate Doctor of Medicine (MD) degree, awarded by the University of Melbourne in 2009. He has been employed as a Consultant in Geenza and ebola disease, and prevention of disease through maternal immunisation.
Dr Snape was acknowledged as an NIHR Clinical Research Network ‘Leading Commercial Principal Investigator’ in 2015 by Dame Sally Davis, Chief Medical Office, and has published over 70 manuscripts relating to immunisation. He is also a member of the Meningitis Research Foundation's Medical Advisory Group.
Dr Snape is an Academic Training Programme Director for Oxford University Clinical Academic Graduate School (OUCAGS), with a particular focus on paediatric academic training.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X. et al, (2023), The Journal of infection, 87, 18 - 26
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X. et al, (2023), The Journal of infection, 86, 540 - 541
Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial.
Calvert A. et al, (2023), Lancet Microbe
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
Goldblatt D. et al, (2023), Vaccine
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH. et al, (2023), J Infect